EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap

Jennifer Davila iD, Sarah H O'Brien, William B Mitchell, Deepa Manwani iD

British Journal of Haematology · 2024-06 · 204 (6) · 2184-2193

DOI: 10.1111/bjh.19428 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 05.04.2024. Verfasst von Jennifer Davila und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, N…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Venous Thromboembolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) arises from beta‐globin gene mutations, with global estimates indicating around 500 000 affected neonates in 2021. In the United States, it is considered rare, impacting fewer than 200 000 individuals. The key pathogenic flaw lies in mutant haemoglobin S, prone to polymerization under low oxygen conditions, causing erythrocytes to adopt a sickled shape. This leads to complications like vascular occlusion, haemolytic anaemia, inflammation and organ damage. Beyond erythrocyte abnormalities however, there is a body of literature highlighting the hypercoagulable state that is likely a contributor to many of the complications we see in SCD. The persistent activation of the coagulation cascade results in thromboembolic events, notably venous thromboembolism (VTE) which is independently associated with increased mortality in both adults and children with SCD. While the increased risk of VTE in the SCD population seems well established, there is a lack of guidelines for thromboprophylaxis in this population. This Wider Perspective will describe the hypercoagulable state and increased thrombosis risk in the SCD population, as well as advocate for the development of evidence‐based guidelines to aid in the prevention of VTE in SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellVenous ThromboembolismHumansAnticoagulantsEvidence Gaps

Stichwörter der Autor:innen

beta globin genesickle cell diseasethromboprophylaxis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Pediatric Hematology-Oncology, Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, USA.
  • Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital/The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Jennifer Davila, Deepa Manwani

Zitieren

APA

Davila, J., O'Brien, S. H., Mitchell, W. B., & Manwani, D. (2024). Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap. British Journal of Haematology, 204(6), 2184-2193. https://doi.org/10.1111/bjh.19428

Vancouver

Davila J, O'Brien SH, Mitchell WB, Manwani D. Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap. British Journal of Haematology. 2024;204(6):2184-2193. doi:10.1111/bjh.19428

BibTeX
@article{Davila2024,
  author = {Davila, Jennifer and O'Brien, Sarah H and Mitchell, William B and Manwani, Deepa},
  title = {Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {6},
  pages = {2184--2193},
  doi = {10.1111/bjh.19428}
}
Kostenlos starten →